TPM3 and cancer: In a similar study of NTRK fusions in cancer patients, those harboring fusions with any of the 3 most frequent partners ETV6, TPM3, and LMNA comprised 22.3% (198/889) of all NTRK‐positive cases, a percentage closer to our observation with MET (13/122 patients, 10.7%).